Patient characteristics according to genetic markers
| Genetic marker . | n . | Median age, y (range) . | P . | Median WBC count, × 109/L (range) . | P . | Response to induction therapy* . | P . | SCT in CR1 . | P . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Good . | Poor . | ND . | |||||||||
| FLT3-ITD | 18 | 14 (2-18) | < .001 | 45.7 (2.2-328) | .003 | 9 | 9 | 0 | 0.005 | 8 | .027 |
| No FLT3-ITD | 167 | 6 (0-17) | 12.9 (0.5-495) | 131 | 30 | 6 | 34 | ||||
| FLT3-TKD mut | 8 | 10 (0-16) | NS | 47.8 (0.5-480) | NS | 7 | 0 | 1 | NS | 0 | NS |
| FLT3-TKD wt | 177 | 6 (0-18) | 14.2 (0.6-495) | 133 | 39 | 5 | 42 | ||||
| Low FLT3 exp† | 75 | 4 (0-17) | NS | 8.7 (0.6-219) | .001 | 55 | 19 | 0 | NS | 19 | NS |
| High FLT3 exp† | 74 | 7 (0-17) | 25.2 (0.5-495) | 56 | 14 | 5 | 17 | ||||
| NPM1 mut | 11 | 12 (0-16) | NS | 42 (2.7-59.5) | NS | 8 | 3 | 0 | NS | 3 | NS |
| NPM1 wt | 174 | 6 (0-18) | 14.2 (0.5-495) | 132 | 36 | 6 | 39 | ||||
| CEBPA single | 3 | 4 (0-14) | NS‡ | 21.3 (5.5-84) | NS† | 2 | 1 | 0 | NS‡ | 0 | |
| CEBPA double | 7 | 10 (5-17) | 34.4 (2.8-126) | 5 | 2 | 0 | 1 | NS‡ | |||
| CEBPA wt | 160 | 6 (0-17) | 16.4 (0.5-495) | 124 | 31 | 5 | 36 | ||||
| WT1 mut | 14 | 9 (3-17) | NS | 7.5 (1.3-150) | NS | 11 | 3 | 0 | NS | 4 | NS |
| WT1 wt | 156 | 6 (0-17) | 18.8 (0.5-495) | 120 | 31 | 5 | 33 | ||||
| Low WT1 exp† | 74 | 3 (0-16) | .001 | 14.8 (0.6-495) | NS | 60 | 13 | 2 | NS | 19 | NS |
| High WT1 exp† | 75 | 9 (0-17) | 13.2 (0.5-480) | 51 | 20 | 3 | 17 | ||||
| Low ERG exp† | 74 | 3 (0-17) | < .001 | 8.9 (0.5-459) | .028 | 61 | 12 | 1 | NS | 14 | NS |
| High ERG exp† | 75 | 9 (0-17) | 19.1 (1.1-495) | 50 | 21 | 4 | 22 | ||||
| Low MN1 exp† | 74 | 3 (0-16) | < .001 | 13.4 (0.5-459) | NS | 61 | 12 | 1 | NS | 13 | NS |
| High MN1 exp† | 75 | 10 (0-17) | 14.2 (1-495) | 50 | 21 | 4 | 23 | ||||
| Low BAALC exp† | 75 | 3 (0-17) | < .001 | 18.9 (0.5-495) | NS | 60 | 12 | 3 | NS | 12 | .019 |
| High BAALC exp† | 74 | 10 (0-17) | 12.9 (1.1-480) | 51 | 21 | 2 | 24 | ||||
| Genetic marker . | n . | Median age, y (range) . | P . | Median WBC count, × 109/L (range) . | P . | Response to induction therapy* . | P . | SCT in CR1 . | P . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Good . | Poor . | ND . | |||||||||
| FLT3-ITD | 18 | 14 (2-18) | < .001 | 45.7 (2.2-328) | .003 | 9 | 9 | 0 | 0.005 | 8 | .027 |
| No FLT3-ITD | 167 | 6 (0-17) | 12.9 (0.5-495) | 131 | 30 | 6 | 34 | ||||
| FLT3-TKD mut | 8 | 10 (0-16) | NS | 47.8 (0.5-480) | NS | 7 | 0 | 1 | NS | 0 | NS |
| FLT3-TKD wt | 177 | 6 (0-18) | 14.2 (0.6-495) | 133 | 39 | 5 | 42 | ||||
| Low FLT3 exp† | 75 | 4 (0-17) | NS | 8.7 (0.6-219) | .001 | 55 | 19 | 0 | NS | 19 | NS |
| High FLT3 exp† | 74 | 7 (0-17) | 25.2 (0.5-495) | 56 | 14 | 5 | 17 | ||||
| NPM1 mut | 11 | 12 (0-16) | NS | 42 (2.7-59.5) | NS | 8 | 3 | 0 | NS | 3 | NS |
| NPM1 wt | 174 | 6 (0-18) | 14.2 (0.5-495) | 132 | 36 | 6 | 39 | ||||
| CEBPA single | 3 | 4 (0-14) | NS‡ | 21.3 (5.5-84) | NS† | 2 | 1 | 0 | NS‡ | 0 | |
| CEBPA double | 7 | 10 (5-17) | 34.4 (2.8-126) | 5 | 2 | 0 | 1 | NS‡ | |||
| CEBPA wt | 160 | 6 (0-17) | 16.4 (0.5-495) | 124 | 31 | 5 | 36 | ||||
| WT1 mut | 14 | 9 (3-17) | NS | 7.5 (1.3-150) | NS | 11 | 3 | 0 | NS | 4 | NS |
| WT1 wt | 156 | 6 (0-17) | 18.8 (0.5-495) | 120 | 31 | 5 | 33 | ||||
| Low WT1 exp† | 74 | 3 (0-16) | .001 | 14.8 (0.6-495) | NS | 60 | 13 | 2 | NS | 19 | NS |
| High WT1 exp† | 75 | 9 (0-17) | 13.2 (0.5-480) | 51 | 20 | 3 | 17 | ||||
| Low ERG exp† | 74 | 3 (0-17) | < .001 | 8.9 (0.5-459) | .028 | 61 | 12 | 1 | NS | 14 | NS |
| High ERG exp† | 75 | 9 (0-17) | 19.1 (1.1-495) | 50 | 21 | 4 | 22 | ||||
| Low MN1 exp† | 74 | 3 (0-16) | < .001 | 13.4 (0.5-459) | NS | 61 | 12 | 1 | NS | 13 | NS |
| High MN1 exp† | 75 | 10 (0-17) | 14.2 (1-495) | 50 | 21 | 4 | 23 | ||||
| Low BAALC exp† | 75 | 3 (0-17) | < .001 | 18.9 (0.5-495) | NS | 60 | 12 | 3 | NS | 12 | .019 |
| High BAALC exp† | 74 | 10 (0-17) | 12.9 (1.1-480) | 51 | 21 | 2 | 24 | ||||
WBC indicates white blood cell; ND, not determined (death before evaluation); mut, mutation; NS, not significant; and exp, expression.
Good response defined as < 5% BM blasts after induction therapy.
Low and high expression defined as above and below the median value, respectively.
CEBPA mutated (single or double) versus CEBPA wt.